StreetAlpha.app
Home › Stocks › CLDX

Celldex Therapeutics, Inc. (CLDX)

Healthcare
$28.04
▼ −1.92%
LAST CLOSE · NOV 17

Celldex develops antibody drugs for mast cell driven and other inflammatory, allergic and autoimmune diseases. It last closed at $28.04 on Nov 17, down 1.92% on the day. The average 12-month price target from 5 analysts is $70.60 (+151.8% from the last close), with a high of $88.00 and a low of $61.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in CLDX, 100% of them bullish and 0% bearish. In the past 30 days there were 1 dark pool print totaling $500K, the largest $500K.

AI Auto Pilots
Is CLDX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$158K
−93.9% vs a year ago
Net income
−$309.1M
−195608.9% margin
EPS (diluted)
−$4.29
Free cash flow
−$259.7M
−164391.8% margin
Valuation
Market cap
$2.2B
78.5M shares
P/E
–
No P/E while losing money
Price to sales
13939.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$27.0M
At Sep 30
Shareholder equity
$649.5M
Shares outstanding
78.5M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $4.7M$4.7MFY2021FY2022: $2.4M$2.4MFY2022FY2023: $6.9M$6.9MFY2023FY2024: $7.0M$7.0MFY2024FY2025: $1.5M$1.5MFY2025

From CLDX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
5firms
5 Buy0 Hold0 Sell
Each firm's latest rating on CLDX in the past 90 days
Average 12-month target
$70.60
▲ 151.8% upside

Based on 5 analysts who set a price target on CLDX in the past 90 days. The average target is $70.60, with a high of $88.00 and a low of $61.00, compared with the last close of $28.04.

Low $61.00Avg $70.60High $88.00
Blue marker: last close $28.04
Highest target$88.00
Average target$70.60
Lowest target$61.00
Latest rating changes
Canaccord GenuityTarget raised
Nov 9Buy$60 → $68
Morgan StanleyTarget raised
Nov 9Buy$57 → $61
Leerink PartnersMaintained
Sep 23Buy$88
Morgan StanleyTarget raised
Sep 23Buy$50 → $57
HC Wainwright & Co.Target raised
Sep 22Buy$42 → $64
DateFirmActionRatingPrice target
Nov 9Canaccord GenuityTarget raisedBuy$60 → $68
Nov 9Morgan StanleyTarget raisedBuy$57 → $61
Sep 23Leerink PartnersMaintainedBuy$88
Sep 23Morgan StanleyTarget raisedBuy$50 → $57
Sep 22HC Wainwright & Co.Target raisedBuy$42 → $64
Loading…

Technical Analysis

CLDX · as of the Nov 17 close · updated after every close
Downtrend

The stock is 5% below its 20 day and 12% below its 50 day average. It is 17% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the swing low (Nov 6) at $27.82, and the nearest resistance the Pivot at $28.28.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 5.1%/day
Key levels
$45.1452 week high+61.0%
$35.31100 day average+25.9%
$32.88200 day average+17.3%
$31.5450 day average+12.5%
$30.40Swing high (Oct 27)+8.4%
$29.4920 day average+5.2%
$29.06Pivot R1+3.6%
$28.28Pivot+0.9%
$28.04Last close
$27.82Swing low (Nov 6)−0.8%
$27.26Pivot S1−2.8%
$22.3352 week low−20.4%
Indicators
RSI (14)40.34Middle of its rangeNeutral
MACD-0.68Above its signal lineBullish
Stochastic19.8Near the bottom of its rangeOversold
ADX (14)20.8Weak trend
Williams %R-87.0Oversold below −80, overbought above −20Oversold
CCI (20)-145.4Oversold below −100, overbought above 100Oversold
Rate of change−5.6%Change over 10 sessionsBearish
ATR (14)$1.43Typical daily range, 5.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CLDX

What happened before

See how CLDX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CLDX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CLDX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
2
100%
Bearish
0
0%
Date span
Sep 1 – Sep 14
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$500K
Largest print
$500K
Loading…

CLDX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲129 buying vs 106 selling
  • ▲Held by funds +4.8 pts
  • ▼Funds holding -6
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding249255−2.4%
In funds' top 10711−36.4%
Held by funds114.0%109.3%+4.8 pts
New / increased36 / 9345 / 106−14.6%
Reduced / sold out64 / 4257 / 21+35.9%
Put/call ratio0.866.02−85.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CLDX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CLDX is in one of them and how their past CLDX trades turned out.

CLDX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CLDX in an article yet. Here's the latest on the wider market.

About Celldex Therapeutics

Celldex is a biopharmaceutical company based in Hampton, New Jersey. It develops antibody drugs aimed at diseases driven by mast cells, including chronic urticaria, prurigo nodularis and atopic dermatitis, as well as other severe inflammatory, allergic and autoimmune conditions. Its main candidates are barzolvolimab, a monoclonal antibody, and a bispecific antibody platform for new inflammatory targets. The company has not yet sold any drugs commercially and is focused on patients whose current treatment options are inadequate.

Headquarters
Hampton, NJ